HRP20200222T4 - Nazalna praškasta formulacija, namijenjena liječenju hipoglikemije - Google Patents
Nazalna praškasta formulacija, namijenjena liječenju hipoglikemije Download PDFInfo
- Publication number
- HRP20200222T4 HRP20200222T4 HRP20200222TT HRP20200222T HRP20200222T4 HR P20200222 T4 HRP20200222 T4 HR P20200222T4 HR P20200222T T HRP20200222T T HR P20200222TT HR P20200222 T HRP20200222 T HR P20200222T HR P20200222 T4 HRP20200222 T4 HR P20200222T4
- Authority
- HR
- Croatia
- Prior art keywords
- powder
- preparation
- preparation according
- mixture
- weight
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 14
- 238000009472 formulation Methods 0.000 title claims 7
- 208000013016 Hypoglycemia Diseases 0.000 title claims 2
- 230000002218 hypoglycaemic effect Effects 0.000 title claims 2
- 229940052404 nasal powder Drugs 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims 15
- 239000000843 powder Substances 0.000 claims 11
- QBHFVMDLPTZDOI-UHFFFAOYSA-N dodecylphosphocholine Chemical compound CCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C QBHFVMDLPTZDOI-UHFFFAOYSA-N 0.000 claims 4
- 229920000858 Cyclodextrin Polymers 0.000 claims 3
- 239000001116 FEMA 4028 Substances 0.000 claims 3
- 102000051325 Glucagon Human genes 0.000 claims 3
- 108060003199 Glucagon Proteins 0.000 claims 3
- 239000000654 additive Substances 0.000 claims 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 3
- 229960004853 betadex Drugs 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 3
- 229960004666 glucagon Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- 230000000996 additive effect Effects 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 239000008365 aqueous carrier Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 239000000693 micelle Substances 0.000 claims 1
- 210000002850 nasal mucosa Anatomy 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 235000005985 organic acids Nutrition 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0043—Non-destructive separation of the package, e.g. peeling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/07—General characteristics of the apparatus having air pumping means
- A61M2205/071—General characteristics of the apparatus having air pumping means hand operated
- A61M2205/073—Syringe, piston type
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (13)
1. Praškasti pripravak koji sadrži glukagon (SEQ ID NO:1), β-ciklodekstrin, te dodecilfosfokolin, gdje je u najmanju ruku dio praha prisutan u fazi naznačenoj time što ima XRPD međusignal kao što je određen difrakcijom rendgenskih zraka na prahu.
2. Pripravak u skladu s patentnim zahtjevom 1, naznačen time što je glukagon prisutan u količini od 5 to 15 posto, težinski.
3. Pripravak u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što dodatno sadrži aditiv kojeg se bira između niskomolekulskih organskih kiselina ili njihovih farmaceutski prihvatljivih soli i estera topljivih u vodi.
4. Pripravak u skladu s patentnim zahtjevom 3, naznačen time što je aditiv limunska kiselina ili natrijev citrat.
5. Pripravak u skladu s patentnim zahtjevom 3 ili patentnim zahtjevom 4, naznačen time što je količina aditiva do 10 posto, težinski.
6. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što se količina β-ciklodekstrina kreće između 44 i 90 posto, težinski.
7. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što se količina dodecilfosfokolina kreće između 5 i 51 posto, težinski.
8. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što je sadržaj vode u pripravku ispod 5 posto, težinski, od ukupne težine pripravka.
9. Nazalni aplikator za praškastu formulaciju, naznačen time što navedeni aplikator sadrži spremnik praškaste formulacije, te praškastu formulaciju koja se nalazi u spremniku, gdje je praškasta formulacija pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 8.
10. Postupak priprave praškastog pripravka u skladu s bilo kojim od patentnih zahtjeva 1 do 8, gdje se navedeni postupak sastoji u koracima
a. dobivanja prve smjese glukagona s dodecilfosfokolinom u vodenom nosaču, gdje je dodecilfosfokolin prisutan u koncentraciji većoj od ili jednakoj koncentraciji kritičnoj za stvaranje micela;
b. dodavanja β-ciklodekstrina u prvu smjesu kako bi se dobilo drugu smjesu;
c. sušenja druge smjese kako bi se dobilo čvrstu formulaciju; i
d. obrade čvrste formulacije kako bi se dobilo jednolični prah, gdje navedeni jednolični prah sadrži u najmanju ruku dio praha u fazi naznačenoj time što ima XRPD međusignal.
11. Postupak u skladu s patentnim zahtjevom 10, naznačen time što se sušenje druge smjese provodi sušenjem smrzavanjem ili sušenjem raspršivanjem druge smjese.
12. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što je namijenjen upotrebi u liječenju hipoglikemije, gdje se pripravak primjenjuje u terapijski djelotvornoj količini u obliku praha na sluznicu nosa pacijenta kojeg treba liječiti.
13. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 13, naznačen time što se pripravak primjenjuje u samo jednu pacijentovu nosnicu.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562117031P | 2015-02-17 | 2015-02-17 | |
| EP16710352.2A EP3258919B2 (en) | 2015-02-17 | 2016-02-16 | Nasal powder formulation for treatment of hypoglycemia |
| PCT/US2016/018003 WO2016133863A1 (en) | 2015-02-17 | 2016-02-16 | Nasal powder formulation for treatment of hypoglycemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20200222T1 HRP20200222T1 (hr) | 2020-05-29 |
| HRP20200222T4 true HRP20200222T4 (hr) | 2022-12-23 |
Family
ID=55538593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200222TT HRP20200222T4 (hr) | 2015-02-17 | 2016-02-16 | Nazalna praškasta formulacija, namijenjena liječenju hipoglikemije |
Country Status (41)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3258919T (pt) * | 2015-02-17 | 2020-03-26 | Lilly Co Eli | Formulação em pó nasal para tratamento da hipoglicemia |
| US11013873B2 (en) * | 2017-01-06 | 2021-05-25 | HealthPartners Institite | Methods for treating patients with impaired awareness of hypoglycemia |
| PE20200678A1 (es) | 2017-06-16 | 2020-06-11 | Zealand Pharma As | Posologias para la administracion de analogos de peptido de tipo glucagon-2 (glp-2) |
| US11844859B2 (en) | 2017-08-20 | 2023-12-19 | Nasus Pharma Ltd. | Dry powder compositions for intranasal delivery |
| CA3071552A1 (en) | 2017-08-20 | 2019-02-28 | Formulex Pharma Innovations Ltd. | Dry powder compositions for intranasal delivery |
| US11413297B2 (en) * | 2017-09-21 | 2022-08-16 | Avanti Polar Lipids, Llc | Therapies for treating and preventing chronic rhinosinusitis |
| TWI771669B (zh) * | 2019-04-26 | 2022-07-21 | 美商美國禮來大藥廠 | 製備穩定胜肽調配物之方法 |
| US10653690B1 (en) | 2019-07-09 | 2020-05-19 | Orexo Ab | Pharmaceutical composition for nasal delivery |
| US10729687B1 (en) | 2019-07-09 | 2020-08-04 | Orexo Ab | Pharmaceutical composition for nasal delivery |
| MX2022011227A (es) | 2020-03-16 | 2022-10-07 | Zealand Pharma As | Formulaciones liquidas de analogos de glucagon. |
| HUE060573T2 (hu) | 2020-05-18 | 2023-03-28 | Orexo Ab | Új gyógyászati készítmény gyógyszerbejuttatáshoz |
| GB202117016D0 (en) | 2021-11-25 | 2022-01-12 | Orexo Ab | New pharmaceutical device |
| JP2024541470A (ja) | 2021-11-25 | 2024-11-08 | オレクソ・アクチエボラゲット | アドレナリンを含む医薬組成物 |
| CN119454909B (zh) * | 2025-01-13 | 2025-04-08 | 上海世领制药有限公司 | 经鼻粘膜给药的胰高血糖素样肽-1受体激动剂的制剂组合物、制备方法、用途及鼻施用器 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58189118A (ja) * | 1982-04-30 | 1983-11-04 | Takeda Chem Ind Ltd | 経鼻投与製剤 |
| NZ222907A (en) * | 1986-12-16 | 1990-08-28 | Novo Industri As | Preparation for intranasal administration containing a phospholipid absorption enhancing system |
| US5179079A (en) | 1986-12-16 | 1993-01-12 | Novo Nordisk A/S | Nasal formulation and intranasal administration therewith |
| US5059587A (en) | 1987-08-03 | 1991-10-22 | Toyo Jozo Company, Ltd. | Physiologically active peptide composition for nasal administration |
| EP0308181A1 (en) * | 1987-09-14 | 1989-03-22 | Novo Nordisk A/S | Trans-mucosal delivery formulations and a method for preparation thereof |
| DK49791D0 (da) * | 1991-03-20 | 1991-03-20 | Novo Nordisk As | Nasalt pulverpraeparat |
| DE19518810A1 (de) | 1995-05-26 | 1996-11-28 | Bayer Ag | Nasal-Applikator |
| JP3098401B2 (ja) * | 1995-07-12 | 2000-10-16 | 株式会社エルティーティー研究所 | 経鼻投与用製剤 |
| JPH11292787A (ja) * | 1995-08-15 | 1999-10-26 | Asahi Chem Ind Co Ltd | 生理活性ペプチドを含有する経粘膜投与製剤 |
| JP4462761B2 (ja) | 1998-03-10 | 2010-05-12 | バルワー エス．アー． | 格納容器に格納された液体製品を投与する装置、及び格納容器の充填方法 |
| EP1061947B1 (en) | 1998-03-13 | 2004-06-16 | Novo Nordisk A/S | Stabilized aqueous glucagon solutions comprising detergents |
| DE69918070T2 (de) | 1998-03-13 | 2005-08-25 | Novo Nordisk A/S | Stabilisierte, wässrige Glukagonlösungen, enthaltend Detergenzien |
| FR2817847B1 (fr) | 2000-12-08 | 2003-03-28 | Tebro | Dispositif de distribution de produit fluide ou pulverulent |
| US7118675B2 (en) | 2002-02-04 | 2006-10-10 | Millipore Corporation | Process for removing protein aggregates and virus from a protein solution |
| KR101036150B1 (ko) | 2003-10-09 | 2011-05-23 | 가부시키가이샤 바이오악티스 | 비강용 분말 약제 투약 장치 |
| US20060074025A1 (en) * | 2003-12-26 | 2006-04-06 | Nastech Pharmaceutical Company Inc. | Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability |
| WO2007065156A2 (en) | 2005-12-02 | 2007-06-07 | Nastech Pharmaceutical Company Inc. | Pharmaceutical formulation for increased epithelial permeability of glucose-regulating peptide |
| US8268791B2 (en) | 2004-08-25 | 2012-09-18 | Aegis Therapeutics, Llc. | Alkylglycoside compositions for drug administration |
| US7994122B2 (en) | 2007-06-15 | 2011-08-09 | Zealand Pharma A/S | Glucagon analogues |
| NZ593813A (en) | 2008-12-15 | 2013-02-22 | Zealand Pharma As | Glucagon analogues |
| EP2799447B1 (en) | 2008-12-15 | 2016-11-23 | Zealand Pharma A/S | Glucagon analogues |
| JP5635530B2 (ja) | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| EA022816B1 (ru) | 2009-07-13 | 2016-03-31 | Зилэнд Фарма А/С | Ацилированные аналоги глюкагона |
| GB2472327B (en) | 2009-07-31 | 2013-03-13 | Shin Nippon Biomedical Lab Ltd | Intranasal granisetron and nasal applicator |
| US9610329B2 (en) * | 2009-10-22 | 2017-04-04 | Albireo Pharma, Inc. | Stabilized glucagon solutions |
| US20130053310A1 (en) | 2010-03-26 | 2013-02-28 | Novo Nordisk A/S | Novel glucagon analogues |
| AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
| MA34383B1 (fr) | 2010-06-24 | 2013-07-03 | Zealand Pharma As | Analogues de glucagon |
| US9216196B2 (en) | 2011-05-27 | 2015-12-22 | Jose Schafik Colazo Handal | Drink for the rapid replacement of calcium ions in the blood stream |
| US8729017B2 (en) | 2011-06-22 | 2014-05-20 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| BR112014015681A2 (pt) | 2011-12-23 | 2019-09-24 | Boehringer Ingelheim Int | análogos de glucagon |
| EP3248642B1 (en) | 2012-06-28 | 2020-04-08 | The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services | Nasal dry powder delivery system for vaccines and other treatment agents |
| FI124134B (en) | 2012-07-02 | 2014-03-31 | One Way Sport Oy | Binding between a ski and a ski boot |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| PT3258919T (pt) | 2015-02-17 | 2020-03-26 | Lilly Co Eli | Formulação em pó nasal para tratamento da hipoglicemia |
-
2016
- 2016-02-16 PT PT167103522T patent/PT3258919T/pt unknown
- 2016-02-16 EA EA201791560A patent/EA034820B1/ru unknown
- 2016-02-16 WO PCT/US2016/018003 patent/WO2016133863A1/en active Application Filing
- 2016-02-16 MA MA052253A patent/MA52253A/fr unknown
- 2016-02-16 HU HUE16710352A patent/HUE049413T2/hu unknown
- 2016-02-16 RS RS20200145A patent/RS59918B2/sr unknown
- 2016-02-16 EP EP16710352.2A patent/EP3258919B2/en active Active
- 2016-02-16 FI FIEP16710352.2T patent/FI3258919T4/fi active
- 2016-02-16 MA MA052252A patent/MA52252A/fr unknown
- 2016-02-16 BR BR112017014994-0A patent/BR112017014994B1/pt active IP Right Grant
- 2016-02-16 SI SI201630611T patent/SI3258919T2/sl unknown
- 2016-02-16 NZ NZ734035A patent/NZ734035A/en unknown
- 2016-02-16 US US15/545,332 patent/US10213487B2/en active Active
- 2016-02-16 EP EP20151175.5A patent/EP3673900B1/en active Active
- 2016-02-16 SG SG11201705640PA patent/SG11201705640PA/en unknown
- 2016-02-16 EP EP20151167.2A patent/EP3673899B1/en active Active
- 2016-02-16 DK DK16710352.2T patent/DK3258919T4/da active
- 2016-02-16 HR HRP20200222TT patent/HRP20200222T4/hr unknown
- 2016-02-16 LT LTEP16710352.2T patent/LT3258919T/lt unknown
- 2016-02-16 UA UAA201707110A patent/UA121874C2/uk unknown
- 2016-02-16 TN TNP/2017/000349A patent/TN2017000349A1/en unknown
- 2016-02-16 MD MDE20180006T patent/MD3258919T3/ro unknown
- 2016-02-16 CR CR20170373A patent/CR20170373A/es unknown
- 2016-02-16 ES ES16710352T patent/ES2775498T5/es active Active
- 2016-02-16 CA CA2975562A patent/CA2975562C/en active Active
- 2016-02-16 CN CN201680010778.8A patent/CN107278154B/zh active Active
- 2016-02-16 KR KR1020177022473A patent/KR102121443B1/ko active Active
- 2016-02-16 MA MA41547A patent/MA41547B1/fr unknown
- 2016-02-16 MY MYPI2017702993A patent/MY175669A/en unknown
- 2016-02-16 MX MX2017010572A patent/MX376200B/es active IP Right Grant
- 2016-02-16 PL PL16710352.2T patent/PL3258919T5/pl unknown
- 2016-02-16 JP JP2017541993A patent/JP6522144B2/ja active Active
- 2016-02-16 AU AU2016220235A patent/AU2016220235B2/en active Active
- 2016-02-16 PE PE2017001397A patent/PE20171334A1/es unknown
-
2017
- 2017-07-02 IL IL253273A patent/IL253273B/en active IP Right Grant
- 2017-07-20 ZA ZA2017/04944A patent/ZA201704944B/en unknown
- 2017-07-31 DO DO2017000179A patent/DOP2017000179A/es unknown
- 2017-08-07 SA SA517382068A patent/SA517382068B1/ar unknown
- 2017-08-08 CL CL2017002031A patent/CL2017002031A1/es unknown
- 2017-08-11 CO CONC2017/0008148A patent/CO2017008148A2/es unknown
- 2017-08-14 SV SV2017005515A patent/SV2017005515A/es unknown
- 2017-08-16 GT GT201700179A patent/GT201700179A/es unknown
- 2017-08-16 PH PH12017501486A patent/PH12017501486A1/en unknown
- 2017-08-17 EC ECIEPI201753843A patent/ECSP17053843A/es unknown
-
2019
- 2019-02-04 US US16/266,640 patent/US12226456B2/en active Active
- 2019-02-27 ZA ZA2019/01241A patent/ZA201901241B/en unknown
- 2019-04-22 JP JP2019080836A patent/JP7094242B2/ja active Active
-
2020
- 2020-02-13 CY CY20201100132T patent/CY1122716T1/el unknown
-
2021
- 2021-04-13 JP JP2021067899A patent/JP7362687B2/ja active Active
- 2021-05-12 AU AU2021203035A patent/AU2021203035B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200222T4 (hr) | Nazalna praškasta formulacija, namijenjena liječenju hipoglikemije | |
| EP2923696B1 (en) | Gastric reflux resistant dosage forms | |
| PH12020500068A1 (en) | Preparation comprising vonoprazan | |
| HRP20192299T1 (hr) | Liječenje nafld i nash | |
| TW201127407A (en) | Carnitine granulate and methods for its production | |
| RU2017143849A (ru) | Твёрдый состав для перорального применения, содержащий иринотекан, и способ его получения | |
| JP2016534142A5 (hr) | ||
| CN104146880B (zh) | 一种固体喷雾及其制备方法 | |
| JP2018527287A5 (hr) | ||
| IL277009B1 (en) | Process for reducing endotoxin in gelatin Process for reducing endotoxin in gelatin | |
| CN102068685A (zh) | 一种特利加压素制剂及其制备方法 | |
| RU2019110980A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| HRP20201696T1 (hr) | Farmaceutska parenteralna formulacija koja sadrži kargluminsku kiselinu | |
| RU2017117662A (ru) | Осажденный карбонат кальция со сниженным содержанием портландита | |
| KR101841987B1 (ko) | 젤 형태의 모델링 마스크 팩 화장료 조성물 | |
| JP2017512194A5 (hr) | ||
| CN104351525A (zh) | 一种蛋鸡饲料添加剂 | |
| RU2015138710A (ru) | Жевательная композиция для перорального приема и способ ее получения | |
| JP2019504843A5 (hr) | ||
| HRP20170541T1 (hr) | Željezni (iii) kazeinsukcinilat i postupak njegovog dobivanja | |
| RU2017114677A (ru) | Перорально распадающаяся твердая фармацевтическая единица дозирования, содержащая контролирующее родовую деятельность вещество | |
| EA201592297A1 (ru) | Композиции агомелатина, содержащие агомелатин в форме сокристаллов | |
| CN107929328A (zh) | 一种适口性好的牛蟾颗粒制作工艺 | |
| CN107950535A (zh) | 一种植物生长调节剂及其应用 | |
| MX2017005080A (es) | Preparacion de citrato de zinc y composiciones para cuidado oral que contienen citrato de zinc. |